NMNH (Reduced NMN)

World's First, Largest, and Longest Human Clinical Trial on NMNH (Reduced NMN) Product Name: β-Nicotinamide Mononucleotide, reduced form (NMNH) CAS No. : 4229-56-5 Phase I clinical trial result has shown UthPeak® NMNH (Reduced NMN) effects on 3X NAD+ INCREMENT 5 Years YOUGNER 35% Boost in ENERGY 31% Improvement in EMOTIONAL WELLNESS UthPeak® has recently obtained the self-affirmed GRAS status for use in selected conventional foods, cellular health supplements, and medical foods. Why UthPeak® NMNH Preclinical and clinical studies to ensure safety and efficacy EffePharm has been dedicated to delivering safe and clinically-backed ingredients top nmn supplements. To ensure the safety of UthPeak® NMNH, comprehensive preclinical toxicology studies have been conducted. UthPeak® is the first NMNH brand globally to conduct the largest and longest human clinical trial on NMNH (reduced NMN). UthPeak® NMNH Clinical Agenda UthPeak® NMNH (reduced NMN) has completed a 90-day Phase I clinical trial with 80 healthy participants, demonstrating promising safety, increased NAD+ levels, and reduced biological age indicators, along with improved emotional well-being and energy support. The forthcoming phase II UthPeak® clinical trials in 2025 will concentrate on assessing NMNH’s potential to enhance consumer-centric well-being factors such as cardioprotection, neuroprotection, and liver protection. Preclinical Studies The completion of extensive animal studies has underscored the potential of UthPeak® in various areas of health and wellness. The ingredient has shown promising results in: ANTI-FATIGUE SLEEP QUALITY IMPROVEMENT CARDIOVASCULAR HEALTH PROMOTION BRAIN FUNCTION ENHANCEMENT ANTI-AGING